危重症患者消化道出血预防的疗效与安全性:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入72项随机对照试验共12660例成人危重症患者,比较质子泵抑制剂(PPI)、组胺-2受体拮抗剂(H2RA)、硫糖铝与安慰剂或不预防对患者重要结局的影响。对于出血最高风险(>8%)或高风险(4-8%)患者,PPI和H2RA相比安慰剂或不预防可能减少临床重要消化道出血(PPI OR 0.61,95%CI 0.42-0.89;H2RA OR 0.46,95%CI 0.27-0.79),但两者可能增加肺炎风险(PPI OR 1.39,95%CI 0.98-2.10;H2RA OR 1.26,95%CI 0.89-1.85)。两者对死亡率可能均无影响(PPI OR 1.06,95%CI 0.90-1.28;H2RA OR 0.96,95%CI 0.79-1.19)。对于低风险患者,出血减少可能不重要。
要点
- 出血最高风险(>8%)或高风险(4-8%)的危重症成人:PPI相比安慰剂或不预防可能减少临床重要消化道出血(OR 0.61,95%CI 0.42-0.89,中等确定性)。
- 出血最高风险(>8%)或高风险(4-8%)的危重症成人:H2RA相比安慰剂或不预防可能减少临床重要消化道出血(OR 0.46,95%CI 0.27-0.79,中等确定性)。
- PPI相比不预防可能增加肺炎风险(OR 1.39,95%CI 0.98-2.10,低确定性);H2RA可能增加肺炎风险(OR 1.26,95%CI 0.89-1.85,低确定性)。
- PPI和H2RA对死亡率可能均无重要影响(PPI OR 1.06,95%CI 0.90-1.28;H2RA OR 0.96,95%CI 0.79-1.19,中等确定性)。
- 对于低出血风险患者,预防所减少的消化道出血可能不重要。
适用人群与场景
- 成人危重症患者,纳入随机对照试验比较消化道出血预防与安慰剂或不预防。
- 按出血风险分层:最高风险(>8%)、高风险(4-8%)、低风险。
诊断标准与关键阈值
- 出血风险分层:最高风险(>8%)、高风险(4-8%)、低风险。
研究设计与关键结果
- 系统评价与网状Meta分析纳入72项随机对照试验共12660例成人危重症患者,比较PPI、H2RA、硫糖铝与安慰剂或不预防。
- 出血最高风险(>8%)患者:PPI相比安慰剂或不预防减少临床重要消化道出血(OR 0.61,95%CI 0.42-0.89;绝对减少3.3%,中等确定性);H2RA相比安慰剂或不预防减少临床重要消化道出血(OR 0.46,95%CI 0.27-0.79;绝对减少4.6%,中等确定性)。
- 出血高风险(4-8%)患者:PPI相比安慰剂或不预防减少临床重要消化道出血(OR 0.61,95%CI 0.42-0.89;绝对减少2.3%,中等确定性);H2RA相比安慰剂或不预防减少临床重要消化道出血(OR 0.46,95%CI 0.27-0.79;绝对减少3.1%,中等确定性)。
- 肺炎风险:PPI相比不预防可能增加肺炎(OR 1.39,95%CI 0.98-2.10;绝对增加5.0%,低确定性);H2RA相比不预防可能增加肺炎(OR 1.26,95%CI 0.89-1.85;绝对增加3.4%,低确定性)。
- 死亡率:PPI对死亡率可能无重要影响(OR 1.06,95%CI 0.90-1.28;绝对增加1.3%,中等确定性);H2RA对死亡率可能无重要影响(OR 0.96,95%CI 0.79-1.19;绝对减少0.9%,中等确定性)。
- 其他结局:结果不支持对艰难梭菌感染、ICU住院时间、医院住院时间或机械通气时间有任何影响(证据确定性不一)。
证据类型、等级与局限
- 证据类型:系统评价与网状Meta分析,纳入72项随机对照试验(12660例患者),使用GRADE评估证据确定性。
- 当低偏倚风险与高偏倚风险研究结果不一致时,采用低偏倚风险研究作为最佳估计。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于出血最高风险(>8%)或高风险(4-8%)的危重症成人,PPI和H2RA可能减少临床重要消化道出血,但可能增加肺炎风险。
- 对于低出血风险患者,预防所减少的消化道出血可能不重要。
- PPI和H2RA对死亡率可能均无重要影响。
指南或共识出处
- BMJ Rapid Recommendation指南委员会对系统评价提供关键监督。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine, in critically ill patients, the relative impact of proton pump inhibitors (PPIs), histamine-2 receptor antagonists (H2RAs), sucralfate, or no gastrointestinal bleeding prophylaxis (or stress ulcer prophylaxis) on outcomes important to patients.
DESIGN: Systematic review and network meta-analysis.
DATA SOURCES: Medline, PubMed, Embase, Cochrane Central Register of Controlled Trials, trial registers, and grey literature up to March 2019.
ELIGIBILITY CRITERIA FOR SELECTING STUDIES AND METHODS: We included randomised controlled trials that compared gastrointestinal bleeding prophylaxis with PPIs, H2RAs, or sucralfate versus one another or placebo or no prophylaxis in adult critically ill patients. Two reviewers independently screened studies for eligibility, extracted data, and assessed risk of bias. A parallel guideline committee (BMJ Rapid Recommendation) provided critical oversight of the systematic review, including identifying outcomes important to patients. We performed random-effects pairwise and network meta-analyses and used GRADE to assess certainty of evidence for each outcome. When results differed between low risk and high risk of bias studies, we used the former as best estimates.
RESULTS: Seventy two trials including 12 660 patients proved eligible. For patients at highest risk (>8%) or high risk (4-8%) of bleeding, both PPIs and H2RAs probably reduce clinically important gastrointestinal bleeding compared with placebo or no prophylaxis (odds ratio for PPIs 0.61 (95% confidence interval 0.42 to 0.89), 3.3% fewer for highest risk and 2.3% fewer for high risk patients, moderate certainty; odds ratio for H2RAs 0.46 (0.27 to 0.79), 4.6% fewer for highest risk and 3.1% fewer for high risk patients, moderate certainty). Both may increase the risk of pneumonia compared with no prophylaxis (odds ratio for PPIs 1.39 (0.98 to 2.10), 5.0% more, low certainty; odds ratio for H2RAs 1.26 (0.89 to 1.85), 3.4% more, low certainty). It is likely that neither affect mortality (PPIs 1.06 (0.90 to 1.28), 1.3% more, moderate certainty; H2RAs 0.96 (0.79 to 1.19), 0.9% fewer, moderate certainty). Otherwise, results provided no support for any affect on mortality, Clostridium difficile infection, length of intensive care stay, length of hospital stay, or duration of mechanical ventilation (varying certainty of evidence).
CONCLUSIONS: For higher risk critically ill patients, PPIs and H2RAs likely result in important reductions in gastrointestinal bleeding compared with no prophylaxis; for patients at low risk, the reduction in bleeding may be unimportant. Both PPIs and H2RAs may result in important increases in pneumonia. Variable quality evidence suggested no important effects of interventions on mortality or other in-hospital morbidity outcomes.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42019126656.
参考来源
- Wang Y, Ye Z, Ge L, et al. Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis. BMJ. 2020. PMID: 31907166. doi:10.1136/bmj.l6744
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。